The future of medicine is in the microbiome
Our live biotherapeutic products are designed from naturally occurring bacteria to support a healthy human microbiome with the power to prevent and treat disease.
Siolta Therapeutics work focuses on understanding how the human microbiome develops and interacts with the body. The key goal is to identify specific microbes—tiny organisms like bacteria—that play important roles in promoting healthy immune development and preventing immune dysfunction. Our research starts with clinical data and microbiome analysis, particularly in infants, as the early stages of life are crucial for setting up a healthy microbiome. By understanding how these microbes interact with the human body, we aim to promote better health outcomes and reduce the risk of diseases that arise from an unhealthy microbiome.Our Precision Symbiotics Platform™ is a specialized approach to develop live biotherapeutics, living medicines composed of naturally occurring bacteria associated with the human body. Our biotherapeutics are designed to prevent or treat diseases by restoring or supporting a healthy balance of microbes in the body.
The human body harbors a complex ecosystem of interconnected microbial life forms collectively referred to as the human microbiome. This ecosystem develops rapidly in early life, and the genetic information it encodes confers functional properties important for human health. In humans, the largest accumulation of microbes resides in the intestinal tract, where they interact with each other and an array of human cells. Microbes are also present on a variety of organs including the skin, urogenital tract, lungs, and mouth, where they promote health or can cause the onset of diseases (dysbiosis). Siolta’s science focuses on designing consortia of microbes that promote microbiome development in early life and in adulthood to prevent immune dysfunction and/or the onset or recurrence of infections.